Mild Alzheimer's, Mild Cognitive Impairment
A Study of LY2599666 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who have mild cognitive impairment due to Alzheimer's Disease (AD) and those with mild-to-moderate AD.
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Your participation could last up to 22 weeks and include 34 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Part B and C Participant must be at least 50 years old
Part B and C Participant must have someone (caregiver or informant/partner) who provides a separate written informed consent to participate
Part B and C Participant must be able and willing to have an MRI (magnetic resonance imaging)